MedPath

Beclomethasone Dipropionate

Generic Name
Beclomethasone Dipropionate
Brand Names
Alanase, Beconase, Propaderm, Qnasl, Qvar, Rivanase AQ
Drug Type
Small Molecule
Chemical Formula
C28H37ClO7
CAS Number
5534-09-8
Unique Ingredient Identifier
5B307S63B2
Background

Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and anti-allergy properties, beclomethasone dipropionate is used in various inflammatory conditions, such as asthma, allergic rhinitis, and dermatoses to reduce symptoms. When inhaled, it is proposed that beclomethasone dipropionate remains active locally in the lung without causing significant side effects associated with systemic corticosteroids. Compared to earlier corticosteroids such as dexamethasone and prednisolone, beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action when administered intranasally.

Indication

糖皮质激素类药。主要用于持续性哮喘的长期治疗。按照支气管哮喘严重程度分级标准,在轻度持续(2级以上)即可使用吸入糖皮质激素治疗;外用适用于对糖皮质激素外用有效的各种非感染性炎症性皮肤病,如亚急性和慢性湿疹、脂溢性皮炎、接触性皮炎、特应性皮炎、局限性神经性皮炎、寻常型银屑病、盘状红斑狼疮、扁平苔癣等。亦可用于常年性变应性鼻炎和季节性变应性鼻炎及血管收缩性鼻炎;亦用于鼻息肉切除术后,预防息肉的再生。

Associated Conditions
Asthma, Bacterial Sinusitis, Chronic Sinusitis, Dermatosis, Fungal skin infection, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Recurrent nasal polyps

A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: BDP/Formoterol Next DPI
First Posted Date
2009-03-16
Last Posted Date
2018-04-13
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
783
Registration Number
NCT00862394
Locations
🇩🇪

Oliver Kornmann - National Coordinator in Germany, Mainz, Germany

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

First Posted Date
2007-11-29
Last Posted Date
2018-07-02
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
210
Registration Number
NCT00565266
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Columbia University Health Sciences, New York, New York, United States

🇺🇸

University of California, San Diego, San Diego, California, United States

and more 7 locations

Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms

Phase 3
Completed
Conditions
Bronchial Asthma
Interventions
Drug: Beclomethasone dipropionate/Salbutamol combination
First Posted Date
2007-07-06
Last Posted Date
2020-08-03
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
283
Registration Number
NCT00497523
Locations
🇵🇱

Zaklad Alergologii Dzieciecej, Bialystok, Poland

🇵🇱

Wojskovy Szpital Klinikzny, Krakow, Poland

🇵🇱

Priwtny Gabinet Pediatriczno - Alergologiczny, Rabka Zdroj, Poland

and more 16 locations

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase 2
Completed
Conditions
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Hematopoietic/Lymphoid Cancer
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Myeloid Leukemia in Remission
Chronic Eosinophilic Leukemia
Chronic Phase Chronic Myelogenous Leukemia
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Interventions
Drug: placebo
Procedure: allogeneic hematopoietic stem cell transplantation
First Posted Date
2007-06-21
Last Posted Date
2021-02-03
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
140
Registration Number
NCT00489203
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2006-11-01
Last Posted Date
2018-07-02
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
288
Registration Number
NCT00394329
Locations
🇺🇸

Kaiser Permanente Medical Center, San Diego, California, United States

🇺🇸

Los Angeles, Kaiser Permanente Allergy Department, Los Angeles, California, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 3 locations

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial
First Posted Date
2006-06-30
Last Posted Date
2018-01-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
97
Registration Number
NCT00346775
Locations
🇺🇸

GSK Investigational Site, Walnut Creek, California, United States

Non-invasive Measures of Distal Lung Disease in Asthmatics

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Servent Diskus
First Posted Date
2005-11-08
Last Posted Date
2021-12-02
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
34
Registration Number
NCT00250341
Locations
🇺🇸

UCLA, Los Angeles, California, United States

7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis

Phase 2
Completed
Conditions
Rhinitis, Allergic, Seasonal
First Posted Date
2005-06-21
Last Posted Date
2005-11-11
Lead Sponsor
Rigel Pharmaceuticals
Target Recruit Count
375
Registration Number
NCT00115089

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

Phase 3
Completed
Conditions
Asthma
First Posted Date
2004-10-11
Last Posted Date
2021-11-23
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
440
Registration Number
NCT00094016
Locations
🇺🇸

NorthEast Medical Research Associates, North Dartmouth, Massachusetts, United States

🇺🇸

The Asthma and Allergy Center, Papillion, Nebraska, United States

🇺🇸

Allergy, Asthma & Dermatology Research Center, Lake Oswego, Oregon, United States

and more 36 locations

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Phase 1
Completed
Conditions
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Graft Versus Host Disease
Breast Cancer
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Neuroblastoma
First Posted Date
2004-04-13
Last Posted Date
2010-04-02
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00010283
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath